Novartis AG is 243.5x more valuable than Xeris Biopharma Holdings, Inc. by market capitalization ($283.13 B vs $1.16 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | XERS | NVS |
|---|---|---|
| Market cap | $1.16 B | $283.13 B |
| US-listed rank | #2530 | #47 |
| Revenue (latest FY) | $291.85M | - |
| Net income (latest FY) | $554.00K | - |
| Net margin | 0.2% | - |
| P/E (trailing FY) | 2098.8 | - |
| SEC filings | 290 | 947 |
Novartis AG is 243.5x more valuable than Xeris Biopharma Holdings, Inc. by market capitalization ($283.13 B vs $1.16 B).
Full pages: Xeris Biopharma Holdings, Inc. and Novartis AG, or browse the full rankings.